Approval from Health Canada for Mesalamine suppositories - Zydus Lifesciences Ltd

Code BSE: 532321 NSE:

Zydus receives approval from Health Canada for Mesalamine suppositories Zydus Lifesciences Limited has received NOC from Health Canada for generic Mesalamine suppositories 1000 mg. Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis. ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).